Media stories about Medtronic PLC (NYSE:MDT) have been trending somewhat positive on Wednesday, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Medtronic PLC earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news stories about the medical technology company an impact score of 46.5230679903936 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern Sentiment’s rankings:
- Medtronic (MDT) Rating Dropped to Sell (investorplace.com)
- Medtronic PLC (MDT) Scheduled to Post Earnings on Tuesday (americanbankingnews.com)
- Medtronic to Present New Clinical Data on Vascular Interventions and Key Symposia at VEITHsymposium 2017 (finance.yahoo.com)
- Seesawing Stocks: Medtronic plc, (NYSE: MDT), FS Investment Corporation, (NYSE: FSIC), Discovery Communications … – Stocks In The News (press release) (tradingnewsnow.com)
Medtronic PLC (NYSE:MDT) opened at $79.16 on Wednesday. Medtronic PLC has a one year low of $69.35 and a one year high of $89.72. The stock has a market capitalization of $107,283.60, a price-to-earnings ratio of 16.89, a P/E/G ratio of 2.15 and a beta of 1.00. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.40 and a current ratio of 1.64.
Medtronic PLC (NYSE:MDT) last issued its earnings results on Tuesday, August 22nd. The medical technology company reported $1.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.04. Medtronic PLC had a return on equity of 12.92% and a net margin of 13.75%. The firm had revenue of $7.39 billion for the quarter, compared to analyst estimates of $7.44 billion. During the same period last year, the company earned $1.03 earnings per share. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. analysts predict that Medtronic PLC will post 4.7 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, October 20th. Shareholders of record on Friday, September 29th were given a $0.46 dividend. This represents a $1.84 annualized dividend and a yield of 2.32%. The ex-dividend date was Thursday, September 28th. Medtronic PLC’s dividend payout ratio is presently 61.95%.
A number of equities analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $94.00 price target on shares of Medtronic PLC in a report on Thursday, November 9th. SunTrust Banks, Inc. restated a “buy” rating and issued a $96.00 price target on shares of Medtronic PLC in a report on Friday, November 3rd. Cowen and Company restated a “buy” rating and issued a $95.00 price target on shares of Medtronic PLC in a report on Friday, November 3rd. BMO Capital Markets restated an “outperform” rating and issued a $89.00 price target (down previously from $92.00) on shares of Medtronic PLC in a report on Tuesday, October 10th. Finally, Leerink Swann restated a “market perform” rating and issued a $85.00 price target (down previously from $88.00) on shares of Medtronic PLC in a report on Monday, October 9th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have given a buy rating to the stock. Medtronic PLC currently has an average rating of “Hold” and a consensus target price of $87.88.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Medtronic PLC (MDT) Stock Price” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.themarketsdaily.com/2017/11/15/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-medtronic-plc-mdt-stock-price.html.
In other news, CEO Omar Ishrak sold 140,407 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $81.63, for a total transaction of $11,461,423.41. Following the transaction, the chief executive officer now directly owns 668,503 shares of the company’s stock, valued at $54,569,899.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Bryan C. Hanson sold 16,000 shares of the firm’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $78.03, for a total value of $1,248,480.00. The disclosure for this sale can be found here. 0.31% of the stock is owned by company insiders.
About Medtronic PLC
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.